Moody's upgrades Biogen (BIIB) from Baa3 to Baa2; outlook Stable
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Join SI Premium – FREE
Moody's upgrades Biogen (Nasdaq: BIIB) from Baa3 to Baa2; outlook Stable
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Stoke Therapeutics adds Bo Cumbo to its board of directors
- Raymond James Assumes Acadia Healthcare (ACHC) at Outperform
- Procore Technologies, Inc (PCOR) PT Lowered to $56 at DA Davidson Amid 'Less Favorable' Construction Dynamics
Create E-mail Alert Related Categories
Credit RatingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
